PUMA Recombinant Rabbit mAb

PUMA (i.e., p53-upregulated modulator of apoptosis, encoded by the BBC3 gene) is a key pro-apoptotic protein belonging to the BH3-only subfamily. Under cellular stress conditions such as DNA damage, oxidative stress, or oncogene activation, it is significantly upregulated as a direct transcriptional target of the transcription factor p53, thereby serving as an important "signal sensor" in the initiation of apoptosis. Through its conserved BH3 domain, this protein binds with high affinity to anti-apoptotic Bcl-2 family members (such as Bcl-2, Bcl-xL, and Mcl-1), neutralizing their inhibitory functions, while also directly binding and activating the pro-apoptotic effector proteins Bax and Bak, promoting their conformational changes and oligomerization on the outer mitochondrial membrane to form pores and induce mitochondrial outer membrane permeabilization (MOMP), leading to the release of apoptotic factors such as cytochrome c and ultimately initiating the caspase cascade that drives the cell toward irreversible apoptosis. PUMA plays a critical role in various tumor suppressive processes, and its inactivation or downregulation is closely associated with chemotherapy resistance and poor prognosis in multiple cancers; meanwhile, aberrant activation of PUMA in ischemic brain injury, myocardial infarction, and neurodegenerative diseases is also recognized as an important pathological mechanism leading to excessive cell death. Consequently, PUMA has emerged as a highly promising dual target in both cancer therapy and neuroprotective strategies—its agonists can synergize with chemotherapeutic agents to induce tumor cell apoptosis, while its inhibitors hold potential for reducing cell loss in pathological conditions such as ischemia-reperfusion injury.